清肺散结丸与长春瑞滨和顺铂联用对晚期非小细胞肺癌的疗效观察

Effect of Qingfeisanjie Capsule Combined with Cisplatin and Vinorelbine on the Treatment of Advanced Non-small Cell Lung Cancer

目的:观察清肺散结丸与长春瑞滨(vinorelbine,NVB)和顺铂(cisplatin,DDP)联合治疗晚期非小细胞肺癌的近期疗效及毒副作用,为临床用药提供参考。方法:选取2010年11月-2012年3月我院收治的晚期非小细胞肺癌患者146例,随机分为对照组和联合组,每组各73例。对照组常规给予长春瑞滨和顺铂(NP方案)治疗,联合组在对照组基础上加以清肺散结丸治疗。观察两组患者的客观有效率、疾病控制率、生活质量改善率和毒副反应的发生情况。结果:对照组患者的客观有效率为42.5%,联合组为46.6%,差异无统计学意义(P>0.05);联合组疾病控制率为85.0%,明显高于对照组的65.8%(P<0.05);联合组生活质量改善情况为68.5%,明显高于对照组的41.1%(P<0.05);联合组Ⅱ度以上白细胞减少的发生率为54.8%,对照组为75.3%;联合组Ⅲ度以上白细胞减少的发生率为17.8%,对照组为37.0%,差异显著具有统计学意义(P<0.05);联合组恶心呕吐的发生率为24.7%,显著优于对照组的49.3%(P<0.05)。结论:NP方案联用清肺散结丸治疗晚期NSCLC能够使患者获益并提高患病期间生活质量,降低骨髓移植和消化系统毒副反应发生。

Objective： To investigate the clinical effects and adverse reactions of Qingfeisanjie capsule combined with Cisplatin and vinorelbine on the treatment of advanced non-small cell lung cancer in order to provide some references for the clinical research. Methods： 146 patients with the advanced NSCLC who were treated in our hospital from November 2010 to March 2012 were selected and randomly divided into the control group and the combination group with 73 cases in each group. The patients in the control group were treated by the conventional method of Cisplatin and Vinorelbine, while the patients in the combination group were treated by Qingfeisanjie capsule combined with Cisplatin and Vinorelbine. Then the response rate, disease control, improvement of life quality and the incidence of adverse reactions were observed and compared between two groups. Results： The response rate of the control group was 42.5%, and 46.6% in combination group with no significant difference. The disease control of the combination group was 85.0% which was higher than 65.8% of the control group （P〈0.05）; The improvement of life quality in the combination group was 68.5% which was higher than 41.1% of the control group （P〈0.05）; The reduction of Ⅱ-Ⅳ leukopenia in the combination group was 54.8% which was better than 75.3% in the control group, and the reduction of Ⅲ-Ⅳ leukopenia in the combination group was 17.8% which was better than 37.0% in the control group with statistically significant differences （P〈0.05）; The incidence of nausea and vomiting in combination group was 24.7% which was lower than 49.3% in the control group （P〈0.05）. Conclusion： Qingfeisanjie capsule could help the patients with advanced NSCLC to improve the life quality and reduce the adverse reactions.